| Literature DB >> 29887581 |
Shunya Nakayama1,2, Hiroshi Koie1, Kiichi Kanayama1, Yuko Katakai3, Yasuyo Ito-Fujishiro1,2, Tadashi Sankai2, Yasuhiro Yasutomi2,4, Naohide Ageyama2.
Abstract
Cardiovascular disease (CVD) has a tremendous impact on the quality of life of humans. While experimental animals are valuable to medical research as models of human diseases, cardiac systems differ widely across various animal species. Thus, we examined a CVD model in cynomolgus monkeys. Laboratory primates are precious resources, making it imperative that symptoms of diseases and disorders are detected as early as possible. Thus, in this study we comprehensively examined important indicators of CVD in cynomolgus monkeys, including arterial blood gas, complete blood count (CBC), biochemistry and cardiac hormones. The control group included 20 healthy macaques showing non-abnormal findings in screening tests, whereas the CVD group included 20 macaques with valvular disease and cardiomyopathy. An increase of red blood cell distribution width was observed in the CBC, indicating chronic inflammation related to CVD. An increase of HCO3 was attributed to the correction of acidosis. Furthermore, development of the CVD model was supported by significant increases in natriuretic peptides. It is suggested that these results indicated a correlation between human CVD and the model in monkeys. Moreover, blood tests including arterial blood gas are non-invasive and can be performed more easily than other technical tests. CVD affected animals easily change their condition by anesthesia and surgical invasion. Pay attention to arterial blood gas and proper respond to their condition are important for research. This data may facilitate human research and aid in the management and veterinary care of nonhuman primates.Entities:
Keywords: arterial blood gas; cardiac hormone; cardiovascular disease; complete blood count; nonhuman primate
Mesh:
Year: 2018 PMID: 29887581 PMCID: PMC6068307 DOI: 10.1292/jvms.18-0124
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Physical characteristics of the cynomolgus monkeys
| Sex | N | Age | Body weight | |||||
|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||||||
| Control | Male | 3 | 28.67 | ± | 4.03 | 6.12 | ± | 1.61 |
| Female | 17 | 19.76 | ± | 6.49 | 4.02 | ± | 0.70 | |
| DCM | Male | 2 | 29.50 | ± | 1.50 | 6.20 | ± | 0.10 |
| Female | 2 | 18.50 | ± | 1.50 | 3.79 | ± | 1.33 | |
| VD | Male | 4 | 24.25 | ± | 6.18 | 5.55 | ± | 0.91 |
| Female | 11 | 29.73 | ± | 5.71 | 3.63 | ± | 0.94 | |
DCM, dilated cardiomyopathy; VD, valvular heart disease.
Fig. 1.Echocardiography of the nonhuman primate CVD model. Echocardiographs of aortic valve stenosis (A) and dilated cardiomyopathy (B) are shown. (A) The subject was 17 years old and weighed 2.11 kg. This animal was diagnosed with aortic stenosis because of the rapid turbulence in the aortic valve from stenosis. (B) The subject was 31 years old and weighed 6.1 kg. This animal was diagnosed with dilated cardiomyopathy, characterized by dilated ventricles and diffuse left ventricle hypokinesis. However, no abnormalities in behavior caused by CVD were observed in each animal. The macaque CVD model shows similar findings in echocardiography.
Results of the arterial blood gas analysis
| Unit | CVD | Control | Significant | |||||
|---|---|---|---|---|---|---|---|---|
| Mean | Median | SD | Mean | Median | SD | |||
| pH | 7.40 | 7.40 | 0.06 | 7.41 | 7.41 | 0.04 | ||
| pCO2 | mmHg | 39.16 | 39.85 | 5.04 | 34.32 | 34.40 | 4.58 | a) |
| pO2 | mmHg | 95.22 | 91.60 | 12.86 | 94.54 | 96.40 | 10.36 | |
| Na+ | mmol/ | 147.30 | 148.00 | 3.59 | 146.76 | 148.00 | 3.62 | |
| K+ | mmol/ | 4.01 | 3.93 | 0.54 | 3.67 | 3.65 | 0.45 | a) |
| Cl | mmol/ | 105.90 | 106.50 | 3.00 | 107.94 | 108.00 | 2.21 | a) |
| Ca++ | mmol/ | 1.22 | 1.23 | 0.08 | 1.18 | 1.19 | 0.06 | |
| HCO3 | mmol/ | 23.74 | 24.25 | 3.23 | 22.42 | 22.30 | 2.79 | |
| BE | mmol/ | –0.78 | 0.05 | 4.11 | –2.56 | –2.60 | 3.42 | |
| ctCO2 | mmol/ | 24.96 | 25.20 | 3.98 | 22.34 | 22.90 | 3.63 | 0.05 |
| Ca++(7.4) | mmol/ | 1.22 | 1.21 | 0.07 | 1.19 | 1.19 | 0.06 | |
| AG | 17.67 | 16.45 | 4.44 | 16.40 | 17.40 | 3.73 | ||
| O2SAT | % | 97.03 | 97.00 | 1.09 | 97.18 | 97.20 | 0.77 | |
| Na/Cl | 1.39 | 1.40 | 0.03 | 1.36 | 1.36 | 0.03 | a) | |
| cHCO3 | mmol/ | 25.40 | 26.00 | 2.99 | 22.82 | 23.00 | 2.73 | a) |
a) P<0.05.
Results of the arterial blood gas analysis
| Unit | DCM | VD | |||||
|---|---|---|---|---|---|---|---|
| Mean | Median | SD | Mean | Median | SD | ||
| pH | 7.41 | 7.42 | 0.06 | 7.40 | 7.41 | 0.05 | |
| pCO2 | mmHg | 37.30 | 35.25 | 6.61 | 39.57 | 40.30 | 4.59 |
| pO2 | mmHg | 102.68 | 103.80 | 6.37 | 94.61 | 90.00 | 12.90 |
| Na+ | mmol/ | 141.75 | 141.50 | 1.48 | 148.33 | 148.00 | 2.09 |
| K+ | mmol/ | 4.20 | 4.51 | 0.54 | 3.90 | 3.77 | 0.47 |
| Cl | mmol/ | 104.00 | 104.00 | 2.55 | 106.13 | 107.00 | 2.85 |
| Ca++ | mmol/ | 1.20 | 1.19 | 0.10 | 1.22 | 1.22 | 0.07 |
| HCO3 | mmol/ | 23.50 | 23.90 | 2.66 | 24.13 | 24.90 | 3.19 |
| BE | mmol/ | –1.30 | –0.75 | 3.20 | –0.23 | 0.80 | 4.11 |
| ctCO2 | mmol/ | 24.13 | 23.15 | 3.53 | 25.49 | 25.70 | 3.99 |
| Ca++(7.4) | mmol/ | 1.20 | 1.20 | 0.07 | 1.23 | 1.21 | 0.07 |
| AG | 14.25 | 14.70 | 1.09 | 18.07 | 17.10 | 4.35 | |
| O2SAT | % | 97.65 | 97.90 | 0.65 | 97.10 | 97.00 | 0.73 |
| Na/Cl | 1.36 | 1.36 | 0.04 | 1.40 | 1.40 | 0.03 | |
| cHCO3 | mmol/ | 21.75 | 21.50 | 3.03 | 26.20 | 26.00 | 2.20 |
Results of CBC analysis
| Unit | CVD | Control | Significant | |||||
|---|---|---|---|---|---|---|---|---|
| Mean | Median | SD | Mean | Median | SD | |||
| WBC | 102/ | 92.21 | 96.00 | 30.91 | 86.73 | 91.00 | 27.24 | |
| RBC | 102/ | 687.53 | 674.00 | 89.62 | 673.55 | 673.50 | 93.04 | |
| HGB | g/d | 13.17 | 12.80 | 1.91 | 13.28 | 13.25 | 1.78 | |
| HCT | % | 46.36 | 45.40 | 6.60 | 45.55 | 46.65 | 5.72 | |
| MCV | f | 67.59 | 67.00 | 5.59 | 67.83 | 67.75 | 2.86 | |
| MCH | 19.23 | 18.70 | 2.07 | 19.78 | 19.45 | 1.34 | ||
| MCHC | g/d | 28.42 | 27.80 | 1.22 | 29.14 | 29.10 | 1.18 | 0.07 |
| PLT | 104/ | 33.25 | 31.70 | 8.50 | 33.53 | 30.95 | 13.16 | |
| RDW | f | 35.68 | 35.50 | 3.47 | 31.55 | 33.50 | 5.34 | a) |
| PDW | f | 11.72 | 11.60 | 1.52 | 11.82 | 11.00 | 2.03 | |
| MPV | f | 9.82 | 9.60 | 1.01 | 10.00 | 10.00 | 1.08 | |
a) P<0.05. WBC, white blood cell count; RBC, red blood cell count; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PLT, platelets; RDW, red blood cell distribution width; PDW, platelet cell distribution width; MPV, mean platelet volume.
Results of CBC analysis
| Unit | DCM | VD | |||||
|---|---|---|---|---|---|---|---|
| Mean | Median | SD | Mean | Median | SD | ||
| WBC | 102/ | 108.25 | 109.50 | 37.50 | 85.64 | 95.50 | 26.89 |
| RBC | 102/ | 594.25 | 626.00 | 80.31 | 715.14 | 711.00 | 76.12 |
| HGB | g/d | 13.10 | 14.00 | 2.58 | 13.23 | 12.80 | 1.73 |
| HCT | % | 43.80 | 45.85 | 6.92 | 47.16 | 45.55 | 6.54 |
| MCV | f | 73.45 | 73.55 | 2.33 | 65.93 | 65.05 | 5.31 |
| MCH | 21.85 | 22.30 | 1.49 | 18.51 | 18.25 | 1.64 | |
| MCHC | g/d | 29.73 | 30.45 | 1.47 | 28.09 | 27.80 | 0.89 |
| PLT | 104/ | 37.60 | 31.55 | 10.80 | 31.09 | 31.75 | 6.55 |
| RDW | f | 34.93 | 36.00 | 2.93 | 35.89 | 34.95 | 3.70 |
| PDW | f | 12.45 | 12.15 | 0.87 | 11.50 | 11.25 | 1.65 |
| MPV | f | 10.63 | 10.45 | 0.83 | 9.56 | 9.40 | 0.96 |
WBC, white blood cell count; RBC, red blood cell count; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PLT, platelets; RDW, red blood cell distribution width; PDW, platelet cell distribution width; MPV, mean platelet volume.
Results of biochemical analyses
| Unit | CVD | Control | Significant | |||||
|---|---|---|---|---|---|---|---|---|
| Mean | Median | SD | Mean | Median | SD | |||
| TP | g/d | 7.30 | 7.40 | 0.58 | 7.35 | 7.25 | 0.53 | |
| ALB | g/d | 3.77 | 3.90 | 0.60 | 3.99 | 3.95 | 0.23 | |
| A/G | 1.12 | 1.10 | 0.33 | 1.22 | 1.22 | 0.19 | ||
| BUN | mg/d | 16.18 | 15.75 | 3.72 | 16.40 | 15.65 | 2.98 | |
| GLU | mg/d | 70.30 | 64.50 | 26.72 | 60.25 | 60.00 | 19.18 | |
| AST | IU/ | 49.65 | 49.50 | 14.18 | 46.65 | 44.00 | 14.02 | |
| ALT | IU/ | 76.85 | 68.00 | 48.53 | 89.40 | 62.50 | 70.14 | |
| CPK | IU/ | 449.40 | 185.00 | 685.89 | 240.45 | 219.50 | 111.13 | |
| LDH | IU/ | 1,032.05 | 1,069.50 | 465.95 | 879.50 | 843.00 | 375.65 | |
| CRP | mg/d | 0.32 | 0.14 | 0.53 | 0.08 | 0.08 | 0.04 | a) |
| CRE | mg/d | 0.55 | 0.50 | 0.20 | 0.65 | 0.60 | 0.18 | |
| GGT | IU/ | 73.00 | 70.00 | 30.27 | 60.33 | 56.00 | 19.92 | |
| hANP | 78.24 | 58.15 | 104.70 | 27.12 | 24.40 | 9.34 | a) | |
| hBNP | 20.23 | 4.36 | 41.43 | 4.95 | 4.00 | 2.88 | 0.06 | |
a) P<0.05. TP, total protein; ALB, albumin; A/G, albumin-globulin ratio; BUN, blood urea nitrogen; GLU, glucose; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPK, creatinine phosphokinase; LDH, lactate dehydrogenase; CRP, C-reactive protein; CRE, serum creatinine; GGT, gamma-glutamyl transferase; hANP, human atrium natriuretic peptide; hBNP, human brain natriuretic peptide.
Results of biochemical analyses
| Unit | DCM | VD | |||||
|---|---|---|---|---|---|---|---|
| Mean | Median | SD | Mean | Median | SD | ||
| TP | g/d | 7.00 | 7.10 | 0.81 | 7.35 | 7.40 | 0.49 |
| ALB | g/d | 3.25 | 3.20 | 0.65 | 3.87 | 3.90 | 0.50 |
| A/G | 0.95 | 0.94 | 0.35 | 1.15 | 1.11 | 0.32 | |
| BUN | mg/d | 18.00 | 17.65 | 3.07 | 15.41 | 14.80 | 3.64 |
| GLU | mg/d | 86.75 | 91.50 | 28.70 | 64.53 | 62.00 | 24.45 |
| AST | IU/ | 53.00 | 51.00 | 13.66 | 49.73 | 50.00 | 14.18 |
| ALT | IU/ | 73.00 | 80.00 | 33.30 | 74.53 | 61.00 | 51.65 |
| CPK | IU/ | 781.00 | 361.00 | 847.31 | 377.13 | 166.00 | 630.36 |
| LDH | IU/ | 870.00 | 793.50 | 345.96 | 1,106.60 | 1,219.00 | 479.86 |
| CRP | mg/d | 0.69 | 0.23 | 0.87 | 0.24 | 0.14 | 0.36 |
| CRE | mg/d | 0.55 | 0.65 | 0.21 | 0.55 | 0.50 | 0.20 |
| GGT | IU/ | 55.00 | 55.00 | 15.00 | 75.53 | 70.00 | 31.93 |
| hANP | 215.63 | 172.80 | 166.92 | 41.73 | 44.40 | 28.61 | |
| hBNP | 68.67 | 28.25 | 70.93 | 4.95 | 4.00 | 2.12 | |
TP, total protein; ALB, albumin; A/G, albumin-globulin ratio; BUN, blood urea nitrogen; GLU, glucose; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPK, creatinine phosphokinase; LDH, lactate dehydrogenase; CRP, C-reactive protein; CRE, serum creatinine; GGT, gamma-glutamyl transferase; hANP, human atrium natriuretic peptide; hBNP, human brain natriuretic peptide.
Fig. 2.Analysis of arterial blood gas parameters in CVD subgroups. cHCO3 and the Na/Cl ratio were especially elevated in valvular heart disease (A, B). Among heart disease groups, valvular heart disease is known to affect metabolism in particular. *P<0.05, one-way ANOVA and Tukey’s correction.
Fig. 3.Analysis of CBC parameters in CVD subgroups. Both CVD subgroups showed similar increases in RDW (A). MCHC was decreased in the VD group (D), and MCV and MCH were increased in the DCM group (B, C). *P<0.05, one-way ANOVA and Tukey’s correction.
Fig. 4.Analysis of biochemical parameters in CVD subgroups. Compared with VD, DCM showed a clear increase in the hANP (A) and hBNP (B). This is related to the mechanism of cardiomyopathy, in which the disorder specifically occurs in the cardiac muscle. *P<0.05, one-way ANOVA and Tukey’s correction.